Phio Pharmaceuticals Files FDA Briefing Package for PH-762 Skin Cancer Program

Phio Pharmaceuticals announced a formal submission to the U.S. FDA regarding nonclinical and clinical data for PH-762, intending to progress to a Phase 2b trial. This filing is a key regulatory milestone, establishing a clear pathway for the clinical development of a potential non-surgical treatment for cutaneous squamous cell carcinoma.